Antimicrobial Resistant (AMR) infections, also called the "silent pandemic" is on the rise. Infections from drug-resistant bacteria (AMR), are now a leading global killer, claiming 1.27 million lives in 2019, more than HIV/AIDS or malaria. We are entering an era when people are dying from otherwise treatable infections https://lnkd.in/dDx-GJSX A major contributor to the potency of AMR is the lack of fast, affordable and accurate diagnostic method for bacterial antibiotic sensitivity. Diagnostics of the antimicrobial susceptibility take 2–3-days to complete and as result forcing doctors all around the world to prescribe antibiotic empirically by “educated guess”, with a staggering 50% error rate. Treatment of patients with incorrect medication prolongs hospitalization, promote adverse medical complications, increases medical costs and accelerate the incidence of antibiotic resistance itself. Fast, accessible, and affordable antibiotic diagnostic tests are an important missing piece in patient care. With it, physicians can prescribe effective treatments The Solution: phenofAST is developing a technology that not only shorten test time and provide AST results in just 3-4 hours from culture, but also doing so at low cost for wide range of bacterial disease. Using lab automation, positive bacteria samples are analyzed in a disposable cassette format containing multiple instances of antibiotic types and concentrations. The Technology: phenofAST’s technology is based on label-free laser diffraction phenomena and detects bacterial cells directly, without the need for expensive and unstable molecular transducers, biochemical or metabolic reactions used elsewhere, making our test not only fast but affordable. The Value proposition: • Faster diagnostic outcome • Comprehensive and affordable method for broad antimicrobial challenges • Preventing inappropriate treatment complications • Shortening hospital length of stay • Reducing healthcare costs across all stakeholders
